American Health Intel Rules. Money. Medicine. Decoded daily.
Subscribe
← All editions
Following a story · 2 updates

Supernus and Indivior merge into $2.2 billion CNS drugmaker

Aug 3, 2026 – Aug 11, 2026

  1. Aug 3, 2026 The Ledger Deal

    Supernus and Indivior merge as equals into $2.2 billion CNS drugmaker

    Indivior shareholders will hold about 56.5 percent of the combined company, named Supernus, Inc., and receive a $1.0 billion cash dividend before closing, in an all-stock deal expected to close in the fourth quarter of 2026.

    Read this issue →
  2. Aug 11, 2026 The Ledger Deal Latest

    Supernus and Indivior merge into $2.2 billion CNS drugmaker

    Supernus Pharmaceuticals and Indivior agreed to combine in an all-stock merger of equals that will trade as Supernus, Inc. on Nasdaq, with Indivior shareholders owning 56.5 percent and receiving a 1 billion dollar special dividend before close.

    Read this issue →